Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases

Jul 3, 2018Current Alzheimer research

Berberine reduces harmful protein buildup in a mouse Alzheimer's model by blocking harmful enzymes and boosting protective ones

AI simplified

Abstract

Berberine (BBR) decreased amyloid-beta levels in the hippocampus of APP/PS1 mice.

  • BBR improved learning and memory deficits in a mouse model of Alzheimer's disease.
  • The treatment significantly reduced levels of BACE1 and sAPP-β in the hippocampus.
  • BBR decreased the expression of components associated with γ-secretase activity.
  • Levels of sAPPα, ADAM10, and ADAM17 significantly increased in BBR-treated mice.

AI simplified

Full Text

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free